According to Zacks, “GenVec, Inc. is a biopharmaceutical company developing novel gene-based therapeutic drugs and vaccines. Each of the Company’s product candidates uses patent-protected technology to deliver genes that produce beneficial proteins. GenVec’s lead product, TNFerade is currently in a pivotal Phase II/III study in locally advanced pancreatic cancer; Phase II studies are in progress in rectal cancer and metastatic melanoma; and Phase I/II studies are in progress in head and neck cancer. GenVec also uses its proprietary adenovector technology to develop vaccines for infectious diseases including HIV, malaria, seasonal and pandemic flu, and foot-and-mouth disease. “
Several other equities research analysts have also commented on the stock. Roth Capital reiterated a buy rating and issued a $2.00 price objective (down previously from $8.00) on shares of GenVec in a research note on Tuesday, July 26th. Rodman & Renshaw reiterated a buy rating and issued a $2.30 price objective on shares of GenVec in a research note on Monday, June 20th.
Shares of GenVec (NASDAQ:GNVC) opened at 0.48 on Monday. The firm’s market capitalization is $10.91 million. The stock has a 50 day moving average of $0.57 and a 200-day moving average of $0.65. GenVec has a 52-week low of $0.35 and a 52-week high of $3.69.
GenVec (NASDAQ:GNVC) last posted its earnings results on Friday, August 5th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.10) by $0.04. GenVec had a negative net margin of 927.05% and a negative return on equity of 83.14%. Equities analysts expect that GenVec will post ($0.29) earnings per share for the current fiscal year.
An institutional investor recently bought a new position in GenVec stock. Sabby Management LLC bought a new position in shares of GenVec Inc. (NASDAQ:GNVC) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 1,625,435 shares of the biopharmaceutical company’s stock, valued at approximately $931,000. Sabby Management LLC owned approximately 7.15% of GenVec at the end of the most recent reporting period. Institutional investors own 26.79% of the company’s stock.
GenVec Company Profile
GenVec, Inc (GenVec) is a clinical-stage biopharmaceutical company, engaged in the development of therapeutics and vaccines. The Company designs, tests and manufactures adenoviral-based product candidates. The Company’s development programs address therapeutic areas, such as hearing loss and balance disorders, as well as vaccines against infectious diseases, including respiratory syncytial virus (RSV), herpes simplex virus (HSV), Enterovirus D68 (EV-D68) and malaria.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for GenVec Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GenVec Inc. and related companies with MarketBeat.com's FREE daily email newsletter.